RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
Institute for Cannabinoid Therapy emblem
Institute for Cannabinoid Therapy
Est. International Education
Regulation by Jurisdiction

Individual modules on regulation, jurisdiction by jurisdiction.

Short, purchasable modules comparing prescribing frameworks, product access and practitioner responsibilities within a single jurisdiction. Educational only — this does not constitute legal advice.

Australia

TGA Special Access and Authorised Prescriber pathways; unregistered medicine framework.

Module · Coming soon

United States

Federal vs. state divergence; FDA-approved cannabinoids and state-level medical programs.

Module · Coming soon

Canada

Health Canada Cannabis Regulations and prescribing under the Access to Cannabis for Medical Purposes framework.

Module · Coming soon

United Kingdom

Unlicensed specials on the NHS and private specialist prescribing under Schedule 2.

Module · Coming soon

Germany

BfArM oversight, statutory insurance reimbursement and evolving pharmacy dispensing rules.

Module · Coming soon

Italy

Ministry of Health authorisation, regional access pathways and magistral preparations.

Module · Coming soon

Switzerland

Swissmedic regulation, recent legal reforms and physician-led access schemes.

Module · Coming soon

New Zealand

Medicinal Cannabis Scheme, minimum quality standards and prescribing responsibilities.

Module · Coming soon

South America

Comparative overview of frameworks across Argentina, Brazil, Colombia, Chile and Uruguay.

Module · Coming soon
Jurisdiction modules are released progressively. Register your interest to be notified as each becomes available.

Regulatory disclaimer. Regulations change frequently and vary by jurisdiction, scope of practice and product classification. These modules are educational summaries and do not constitute legal advice. Practitioners remain responsible for understanding and complying with the laws applicable within their own jurisdiction.